In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

The stock's fall snapped a seven-day winning streak.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Sangamo Therapeutics has higher earnings, but lower revenue than Novavax. Novavax is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

SB also argued that although it would sell its finished product to Biogen MA Inc. (a U.S. company) in a state other than West Virginia, it would not distribute, market or otherwise sell the ...

Exercise can make a significant difference for patients with SMA by working alongside other medical advancements to improve their quality of life. As a child, Mitchell Choma rarely sat still ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...